Goldman Sachs Group Inc Cure Vac N.V. Transaction History
Goldman Sachs Group Inc
- $596 Billion
- Q1 2025
A detailed history of Goldman Sachs Group Inc transactions in Cure Vac N.V. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 267,404 shares of CVAC stock, worth $1.19 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
267,404
Previous 267,404
-0.0%
Holding current value
$1.19 Million
Previous $740,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
21 transactions
Others Institutions Holding CVAC
# of Institutions
94Shares Held
10.7MCall Options Held
75.1KPut Options Held
86.7K-
Black Rock Inc. New York, NY2.25MShares$10.1 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.82MShares$8.1 Million0.0% of portfolio
-
Bill & Melinda Gates Foundation Seattle, WA1.57MShares$7 Million10.6% of portfolio
-
Ubs Group Ag843KShares$3.76 Million0.0% of portfolio
-
Gsa Capital Partners LLP London, X0308KShares$1.37 Million0.08% of portfolio
About CureVac N.V.
- Ticker CVAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,467,008
- Market Cap $836M
- Description
- CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...